Zhejiang Garden Biopharmaceutical Co.,Ltd. (SHE:300401)

SHE:300401 Income Statement

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Operating Revenue	1,217	1,221	1,082	1,397	1,107	650.39
Other Revenue	22.45	22.45	12.93	20.39	9.75	9.05
Revenue	1,239	1,243	1,095	1,418	1,117	659.44
Revenue Growth (YoY)	11.88%	13.58%	-22.78%	26.89%	69.40%	-8.21%
Cost of Revenue	523.03	519.59	441.4	486.37	350.66	281.47
Gross Profit	716.37	723.7	653.25	931.14	766.44	377.97
Selling, General & Admin	275.86	308.87	378.77	444.55	257.61	93.3
Research & Development	79.6	83.78	90.91	70.34	59.28	45.09
Other Operating Expenses	14.45	13.24	16.44	16.24	3.48	5.61
Operating Expenses	371.67	407.87	483.74	533.66	320.69	144.04
Operating Income	344.69	315.83	169.51	397.48	445.75	233.93
Interest Expense	-33.32	-35.63	-38.41	-21.82	-10.81	-16.91
Interest & Investment Income	11.57	11.01	20.54	13.75	32.49	26.87
Currency Exchange Gain (Loss)	6.31	6.31	7.02	11.1	-2.79	-7.22
Other Non Operating Income (Expenses)	5.46	-0.32	-0.3	-0.65	-0.19	-0.25
EBT Excluding Unusual Items	334.71	297.19	158.36	399.86	464.46	236.42
Gain (Loss) on Sale of Investments	1.25	0.25	-0.34	-2.83	0.4	-
Gain (Loss) on Sale of Assets	0.15	31.53	-0.04	17.8	76.22	0.02
Asset Writedown	-0.44	-0.44	-0.22	-1.01	-0.09	-0.43
Other Unusual Items	30.17	30.17	53.27	28.67	48.38	51.7
Pretax Income	365.83	358.69	211.04	442.48	589.37	287.71
Income Tax Expense	51.6	49.48	18.7	58.76	75.42	27.09
Earnings From Continuing Operations	314.24	309.21	192.35	383.72	513.94	260.62
Minority Interest in Earnings	0.01	0	-	-	-30.18	2.6
Net Income	314.24	309.21	192.35	383.72	483.77	263.22
Net Income to Common	314.24	309.21	192.35	383.72	483.77	263.22
Net Income Growth	35.47%	60.76%	-49.87%	-20.68%	83.79%	-23.42%
Shares Outstanding (Basic)	542	542	550	548	544	506
Shares Outstanding (Diluted)	576	595	601	548	544	506
Shares Change (YoY)	-5.46%	-1.07%	9.65%	0.85%	7.38%	6.04%
EPS (Basic)	0.58	0.57	0.35	0.70	0.89	0.52
EPS (Diluted)	0.55	0.52	0.32	0.70	0.89	0.52
EPS Growth	43.29%	62.50%	-54.29%	-21.35%	71.15%	-27.78%
Free Cash Flow	-12.35	-13.97	-84.57	-2.89	-203.33	-166.46
Free Cash Flow Per Share	-0.02	-0.02	-0.14	-0.01	-0.37	-0.33
Dividend Per Share	0.114	0.114	0.071	0.140	0.188	0.103
Dividend Growth	60.56%	60.56%	-49.29%	-25.53%	82.52%	-
Gross Margin	57.80%	58.21%	59.68%	65.69%	68.61%	57.32%
Operating Margin	27.81%	25.40%	15.48%	28.04%	39.90%	35.47%
Profit Margin	25.35%	24.87%	17.57%	27.07%	43.31%	39.91%
Free Cash Flow Margin	-1.00%	-1.12%	-7.72%	-0.20%	-18.20%	-25.24%
EBITDA	505.77	471.35	302.82	458.27	490.2	279.59
EBITDA Margin	40.81%	37.91%	27.66%	32.33%	43.88%	42.40%
D&A For EBITDA	161.07	155.52	133.31	60.79	44.45	45.66
EBIT	344.69	315.83	169.51	397.48	445.75	233.93
EBIT Margin	27.81%	25.40%	15.48%	28.04%	39.90%	35.47%
Effective Tax Rate	14.10%	13.80%	8.86%	13.28%	12.80%	9.41%
Revenue as Reported	1,239	1,243	1,095	1,418	1,117	659.44
Advertising Expenses	-	2.37	0.97	0.7	0.8	1.13

Updated Oct 17, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.